Kiniksa Pharmaceuticals International, plc (KNSA)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Does Kiniksa Pharmaceuticals International, plc (KNSA) Have the Potential to Rally 35.96% as Wall Street Analysts Expect?
The mean of analysts' price targets for Kiniksa Pharmaceuticals International, plc (KNSA) points to a 36% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Here's Why Momentum in Kiniksa Pharmaceuticals International, plc (KNSA) Should Keep going
Kiniksa Pharmaceuticals International, plc (KNSA) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Kiniksa Pharmaceuticals International, plc (KNSA) Q2 2025 Earnings Call Transcript
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA ) Q2 2025 Earnings Call July 29, 2025 8:30 AM ET Company Participants Jonathan Kirshenbaum - Investor Relations Officer Mark A. Ragosa - Senior VP & CFO Ross Michael Moat - Executive VP & Chief Commercial Officer Sanj K.
Kiniksa Pharmaceuticals International, plc (KNSA) Tops Q2 Earnings and Revenue Estimates
Kiniksa Pharmaceuticals International, plc (KNSA) came out with quarterly earnings of $0.23 per share, beating the Zacks Consensus Estimate of $0.18 per share. This compares to a loss of $0.06 per share a year ago.
Kiniksa Pharmaceuticals: Making Steady Progress
Kiniksa Pharmaceuticals posted strong Q1 results last week, beating expectations and raising 2025 ARCALYST net sales guidance to $590-$605 million, up from $560-$580 million. Analyst firms are optimistic, with firms like Goldman Sachs, Wedbush, and Jefferies assigning Buy ratings and price targets ranging from $32 to $45 on the shares. Kiniksa also has a solid balance sheet with nearly $270 million in cash and no long-term debt.
Kiniksa Pharmaceuticals International, plc (KNSA) Q1 2025 Earnings Call Transcript
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA ) Q1 2025 Results Conference Call April 29, 2025 8:30 AM ET Company Participants Jonathan Kirshenbaum - Investor Relations Sanj Patel - Chairman & Chief Executive Officer Ross Moat - Chief Commercial Officer Mark Ragosa - Chief Financial Officer John Paolini - Chief Medical Officer Conference Call Participants Mary Kate - Citi Roger Song - Jefferies Eva Fortea-Verdejo - Wells Fargo Anupam Rama - JPMorgan David Nierengarten - Wedbush Operator Good day, and thank you for standing by. Welcome to the Kiniksa Pharmaceuticals First Quarter 2025 Earnings Conference Call.
Kiniksa Pharmaceuticals, Ltd. (KNSA) Tops Q1 Earnings and Revenue Estimates
Kiniksa Pharmaceuticals, Ltd. (KNSA) came out with quarterly earnings of $0.11 per share, beating the Zacks Consensus Estimate of $0.02 per share.
Is Kiniksa Pharmaceuticals (KNSA) Outperforming Other Medical Stocks This Year?
Here is how Kiniksa Pharmaceuticals, Ltd. (KNSA) and Krystal Biotech, Inc. (KRYS) have performed compared to their sector so far this year.
Wall Street Analysts Predict a 64.8% Upside in Kiniksa Pharmaceuticals (KNSA): Here's What You Should Know
The consensus price target hints at a 64.8% upside potential for Kiniksa Pharmaceuticals (KNSA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
How Much Upside is Left in Kiniksa Pharmaceuticals (KNSA)? Wall Street Analysts Think 58.6%
The average of price targets set by Wall Street analysts indicates a potential upside of 58.6% in Kiniksa Pharmaceuticals (KNSA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Surging Earnings Estimates Signal Upside for Kiniksa Pharmaceuticals (KNSA) Stock
Kiniksa Pharmaceuticals (KNSA) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Kiniksa Pharmaceuticals (KNSA) Soars 5.8%: Is Further Upside Left in the Stock?
Kiniksa Pharmaceuticals (KNSA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
